Distribution Dates for shares and ADRs in Accustem
Updated : 12:30
Accustem Sciences Limited
("Accustem" or the "Company")
Distribution Dates for shares and ADRs in Accustem Sciences Limited
Accustem Sciences Limited is pleased to announce that the Forms 20-F and F-6 filed by Accustem Sciences Limited with the SEC were declared effective on 1 July 2021, enabling the completion of the in specie distribution and spin out of Accustem from Tiziana Life Sciences plc. The SEC filings can be viewed at https://sec.report/CIK/0001850767 and there is also a link to them on the Accustem website: www.accustem.com.
If you held ordinary shares in Tiziana Life Sciences plc ("Tiziana") on the UK Record Date
The timetable for the holders of Tiziana ordinary shares (traded on the London Stock Exchange) held in CREST and Certificated form is as follows:
Demerger Record Time: 7:00 a.m. on 30 October 2020
Ex-entitlement date for Accustem Shares: 2 November 2020
CREST accounts credited with Accustem Shares: 8 July 2021*
Certificates for Accustem Shares for those shareholders
holding their Tiziana Life Sciences plc in certificated form: by 18 July 2021
* replacing allocation placeholders currently showing
If you held Tiziana ADSs (traded on the US Nasdaq Market) on the DR Record Date
The timetable for the holders of Tiziana ADSs (traded on the Nasdaq market) is set out below. You should also review the notice posted by JP Morgan, the ADR depositary bank, which can be found at https://www.adr.com/drprofile/88875G101
Announcement Tiziana CUSIP: 88875G101
Corporate Action Type: Spin Off with DR Distribution
Spin Off Issuer Name: Accustem Sciences Limited
Spin Off DR CUSIP: 00442Y101
DR Distribution Rate: 1 new Accustem DR(s) issued for every 1 existing Tiziana DR held on DR Record Date
Tax Withholding Rate: n/a
DR Record Date: November 6, 2020
DR Payment Date: July 14, 2021
DR Issuance and Cancellation Books close Date: October 28, 2020
DR Issuance and Cancellation Books reopen Date: July 19, 2021
Fees: Issuance fee: $nil per DR issued
This will formally conclude the separation of Accustem from Tiziana Life Sciences plc and no further information concerning Accustem will be published on the Tiziana website. Regular updates will be posted to the Accustem website.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.